5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: A population based study

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 731-736

  Bernstein, Charles N ^a   Nugent, Zoann ^a   Blanchard, James F ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; SAMPLE SIZE; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEX FACTORS; TREATMENT FAILURE;

EID: 79953793925     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.50     Document Type: Article

References (30)

1. Moody GA, Jayanthi V, Probert CS et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83. (Pubitemid 26413548)
2. Pinczowski D, Ekbom A, Baron J et al Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study Gastroenterology 1994;107:117-20. (Pubitemid 24195353)
3. Teaden J, Abrams K, Ekbom A et al Colorectal cancer prevention in ulcera-tive colitis: a case-control study. Aliment Pharmacol Ter 2000;14:145-53. (Pubitemid 30088290)
4. Velayos FST, Jonathan P, Walsh JM et al effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis ofobservational studies. Am J Gastroenterol 2005;100:1345-53. (Pubitemid 40904360)
5. Bernstein CN, Metge C, Blanchard JF et al Does the use of 5-aminosali-cylates in Infammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-8. (Pubitemid 38020124)
6. Roos LL, Mustard CA, Nicol JP. Registries and administrative data: organization and accuracy Med Care 1993; 31: 201-12.
7. Roos LL, Gupta S, Soodeen RA et al Data quality in an information-rich environment: Canada as an example. Can J Aging 2005;24 (Suppl1): 153-70. (Pubitemid 40910640)
8. Kozyrskyj AL, Mustard CA. Validation of an electronic, population-based prescription database. Ann Pharmacother 1998;32:1152-7. (Pubitemid 28543459)
9. Roos LL, Nicol JP. A research registry: uses, development, and accuracy J Clin Epidemiol 1999; 52: 39-47. (Pubitemid 29064272)
10. Bernstein CN, Blanchard JF, Rawsthorne P et al Te epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study Am J Epidemiol 1999;149:916-24. (Pubitemid 29230706)
11. Tellison JH, Wu XC, McLaughlin C et al (eds). Cancer in North America: 1999-2003. Volume One: Incidence. North American Association of Central Cancer Registries: Springfeld, IL, 2006, p II-325.
12. Cox DR. Regression models and life tables. J Royal Stat Soc 1972, Series B; 20:187-220.
13. Rutter M, SaundersB, WilkinsonK et al. SeverityofInfammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
14. Van Staa TP, Card T, Logan RF et al 5-Aminosalicylate use and colorectal cancer risk in Infammatory bowel disease: a large epidemiological study Gut 2005;54:1573-8. (Pubitemid 41531774)
15. Rubin DT, LoSavio A, Yadron N et al Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:1346-50. (Pubitemid 44716744)
16. Lashner BA, Provencher KS, Seidner DL et al Te effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32. (Pubitemid 27008982)
17. Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. Te impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study Dis Colon Rectum 2001;44:77-85. (Pubitemid 32105878)
18. Velayos FS, Lofus Jr EV Jess Tet al Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study Gastroenterology 2006;130:1941-9. (Pubitemid 43816957)
19. Jess T, Lofus Jr EV Velayos FS et al Risk factors for colorectal neoplasia in Infammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007;102:829-36. (Pubitemid 46496613)
20. Terdiman JP, Steinbuch M, Blumentals WA et al 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with Infammatory bowel disease. Infamm Bowel Dis 2007;13:367-71. (Pubitemid 46668239)
21. Ul lman T, Croog V Harpaz N et al Progression to colorectal neoplasia in ulcerative colitis: efect of mesalamine. Clin Gastroenterol Hepatol 2008;6:1225-30.
22. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of Infammatory bowel disease. Gastroenterol Clin North Am 2006;35:675-712. (Pubitemid 44314185)
23. Stange EF. Review article: the effect of aminosalicylates and immunomodu-lation on cancer risk in infammatory bowel disease. Aliment Pharmacol Ter 2006;24 (Suppl 3): 64-7. (Pubitemid 44326423)
24. Munkholm P, Lofus Jr EV Reinacher-Schick A et al Prevention of colorectal cancer in Infammatory bowel disease: value of screening and 5-aminosalicylates. Digestion 2006;73:11-9. (Pubitemid 43800656)
25. Rubin DT, Cruz-Correa MR, Gasche C, et al., for the 5-ASA in Colorectal Cancer Prevention Meeting Group. Colorectal cancer prevention in inf am-matory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Infamm Bowel Dis 2008;14:265-74. (Pubitemid 351288050)
26. Spiegel BMR, Ho W, Esrailian E et al Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 2009; 7: 168-74.
27. Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Infamm Bowel Dis 2009;15:630-8.
28. Robinson A, Tompson DG, Wilkin D, et al, Northwest Gastrointestinal Research Group. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001;358:976-81. (Pubitemid 32913524)
29. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4. (Pubitemid 24019346)
30. Connell WR Lennard-Jones JE, Williams CB et al Factors af ecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44. (Pubitemid 24294554)